PULMONARY
THERAPY
FOR
CYSTIC
FIBROSIS
PP
2537
THIS
REPORT
SUMMARIZES
SELECTED
ASPECTS
OF
PULMONARY
THERAPY
FOR
CYSTIC
FIBROSIS
SINCE
THE
RESULTS
OF
CHRONIC
BRONCHOPULMONARY
INFECTION
ARE
THE
CAUSE
OF
DEATH
IN
MOST
CF
PATIENTS
IMPROVED
PATIENT
SURVIVAL
PATTERNS
MAY
POSSIBLY
BE
ATTRIBUTED
IN
LARGE
PART
TO
IMPROVEMENTS
IN
ANTIBIOTIC
THERAPY
AND
INCREASED
THERAPEUTIC
AGGRESSIVENESS
MIST
TENT
THERAPY
WAS
DEFINED
AND
INITIATED
IN
THE
1950S
BUT
LATER
STUDIES
OF
MIST
TENT
THERAPY
HAVE
NOT
SHOWN
BENEFICIAL
RESPONSE
IN
MANY
PATIENTS
SELECTED
FOR
STUDY
INTERMITTENT
AEROSOL
THERAPY
CONTINUES
TO
BE
EMPLOYED
BY
MANY
PHYSICIANS
TO
DELIVER
MEDICATION
RATHER
THAN
BULK
LIQUID
TO
THE
BRONCHIAL
MUCOSA
PULMONARY
ENDOSCOPY
AND
LAVAGE
EXPECTORANTS
ALLERGIC
ASPERGILLOSIS
PNEUMOTHORAX
LOBECTOMY
AND
HEMOPTYSIS
ARE
ALSO
EXAMINED
